Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H37NO13.ClH |
| Molecular Weight | 680.096 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3C[C@@](O)(CC4=C3C(O)=C5C(=O)C6=C(C=CC=C6)C(=O)C5=C4O)C(=O)CO)O[C@H]2C
InChI
InChIKey=BSRQHWFOFMAZRL-BODGVHBXSA-N
InChI=1S/C32H37NO13.ClH/c1-12-26(37)17(33)7-21(43-12)46-31-13(2)44-22(8-18(31)35)45-19-10-32(42,20(36)11-34)9-16-23(19)30(41)25-24(29(16)40)27(38)14-5-3-4-6-15(14)28(25)39;/h3-6,12-13,17-19,21-22,26,31,34-35,37,40-42H,7-11,33H2,1-2H3;1H/t12-,13-,17-,18-,19-,21-,22-,26+,31+,32-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C32H37NO13 |
| Molecular Weight | 643.6351 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sabarubicin (previously known as MEN-10755), a disaccharide analog of doxorubicin that was developed by Menarini Pharmaceuticals for the treatment of solid tumors, including small cell lung cancer and prostate cancer. Sabarubicin exhibits a superior antitumor efficacy, presumably related to the activation of p53-independent apoptosis. The drug participated in phase II clinical trials to study its effectiveness in treating patients who have progressive prostate cancer that has not responded to hormone therapy and in chemotherapy-naive patients with extensive stage small cell lung cancer. On 21 December 2004, the European Commission granted the orphan designation to Menarini for sabarubicin for the treatment of small cell lung cancer.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men10755. | 2010-02-15 |
|
| Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells. | 2008-01-30 |
|
| Sabarubicin. | 2008 |
|
| Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart. | 2000-09 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:02:47 GMT 2025
by
admin
on
Mon Mar 31 19:02:47 GMT 2025
|
| Record UNII |
2Y0GD160CC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID80873335
Created by
admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
|
PRIMARY | |||
|
169317-77-5
Created by
admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
|
PRIMARY | |||
|
151896
Created by
admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
|
PRIMARY | |||
|
2Y0GD160CC
Created by
admin on Mon Mar 31 19:02:47 GMT 2025 , Edited by admin on Mon Mar 31 19:02:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |